{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:22:22Z","timestamp":1774596142610,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the long-term risk and survival of third primary cancers (TPCs) among prostate first primary cancer (FPC) survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based cohort of 13 222 males with a prostate FPC diagnosed between 2000 and 2009, registered by the North Region Cancer Registry of Portugal, was followed until 2021 for TPCs and vital status. We estimated the cumulative incidence of TPCs and the risk of death among TPCs. TPCs were compared to matched patients with a second primary cancer (SPC) only (1:1, by age group, the time between FPC and SPC, and SPC site) for risk and adjusted hazard of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For a period of up to 22 years after a prostate cancer diagnosis, 169 TPCs were identified, predominantly, in digestive, intrathoracic, and urinary tract organs; this corresponds to 15- and 20-year cumulative incidences [95% confidence interval (CI)] of 1.2% (1.0\u20131.4%) and 1.5% (1.2\u20131.8%), respectively, among the FPCs, and 9.1% (7.6\u201310.5%) and 12.0% (8.2\u201315.9%), respectively, among the SPCs. The 15-year all-cause cumulative mortality was 88.2% (82.2\u201394.3%) among TPCs and 75.7% (69.6\u201381.7%) among SPC only patients; the corresponding age-adjusted hazard ratio (95% CI) was 1.79 (1.37\u20132.34).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among males with a prostate FPC that are diagnosed with an SPC, just over 10% are expected to be diagnosed with a TPC within 20 years, and these have a nearly two-fold higher death hazard than those with an SPC only.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000000977","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:00:25Z","timestamp":1747915225000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risk and survival of third primary cancers in a population-based cohort of prostate cancer survivors"],"prefix":"10.1097","volume":"35","author":[{"given":"Patr\u00edcia","family":"S\u00e1","sequence":"first","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade P\u00fablica e Forenses e Educa\u00e7\u00e3o M\u00e9dica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal"}]},{"given":"Jos\u00e9","family":"Taveira-Barbosa","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade P\u00fablica e Forenses e Educa\u00e7\u00e3o M\u00e9dica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal"},{"name":"Servi\u00e7o de Epidemiologia, Instituto Portugu\u00eas de Oncologia do Porto, Porto, Portugal"}]},{"given":"Samantha","family":"Morais","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio Associado Para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR), Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Porto, Portugal"}]},{"given":"Teresa","family":"Garcia","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade P\u00fablica e Forenses e Educa\u00e7\u00e3o M\u00e9dica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal"},{"name":"Servi\u00e7o de Epidemiologia, Instituto Portugu\u00eas de Oncologia do Porto, Porto, Portugal"},{"name":"Grupo de Investiga\u00e7\u00e3o em Epidemiologia, Resultados, Economia e Gest\u00e3o em Oncologia - Centro de Investiga\u00e7\u00e3o (CI-IPOP) & Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Rede de Investiga\u00e7\u00e3o em Sa\u00fade), Instituto Portugu\u00eas de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal"}]},{"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Epidemiologia, Instituto Portugu\u00eas de Oncologia do Porto, Porto, Portugal"},{"name":"Grupo de Investiga\u00e7\u00e3o em Epidemiologia, Resultados, Economia e Gest\u00e3o em Oncologia - Centro de Investiga\u00e7\u00e3o (CI-IPOP) & Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Rede de Investiga\u00e7\u00e3o em Sa\u00fade), Instituto Portugu\u00eas de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal"},{"name":"Departamento Estudos de Popula\u00e7\u00f5es, Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal"}]},{"given":"Nuno","family":"Lunet","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade P\u00fablica e Forenses e Educa\u00e7\u00e3o M\u00e9dica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal"},{"name":"Laborat\u00f3rio Associado Para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR), Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Porto, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review.","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1002\/cam4.1764","article-title":"Prostate cancer survivors: risk and mortality in second primary cancers.","volume":"7","author":"Chattopadhyay","year":"2018","journal-title":"Cancer Med"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41391-018-0089-y","article-title":"Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.","volume":"22","author":"Chattopadhyay","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"e48380","DOI":"10.2196\/48380","article-title":"Risk of subsequent primary cancers among adult-onset 5-year cancer survivors in South Korea: retrospective cohort study.","volume":"10","author":"Choi","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.28769","article-title":"Risk of second primary tumors in men diagnosed with prostate cancer: a population\u2010based cohort study.","volume":"120","author":"Davis","year":"2014","journal-title":"Cancer"},{"key":"R6-20260327","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.12.278","article-title":"Cancer-specific mortality after radical prostatectomy versus radiotherapy in incidental prostate cancer.","author":"Di Bello","year":"2025","journal-title":"Urol Oncol"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"e0175217","DOI":"10.1371\/journal.pone.0175217","article-title":"Risk of second primary malignancies among patients with prostate cancer: a population-based cohort study.","volume":"12","author":"Fan","year":"2017","journal-title":"PLoS One"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"e038937","DOI":"10.1136\/bmjopen-2020-038937","article-title":"Regional differences in tobacco smoking and lung cancer in Portugal in 2018: a population-based analysis using nationwide incidence and mortality data.","volume":"10","author":"Forjaz","year":"2020","journal-title":"BMJ Open"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"e2414582","DOI":"10.1001\/jamanetworkopen.2024.14582","article-title":"Access to prostate-specific antigen testing and mortality among men with prostate cancer.","volume":"7","author":"Iyer","year":"2024","journal-title":"JAMA Network Open"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2340\/1651-226X.2024.24334","article-title":"The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer.","volume":"63","author":"Jahrei\u00df","year":"2024","journal-title":"Acta Oncol"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"e0140693","DOI":"10.1371\/journal.pone.0140693","article-title":"Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study.","volume":"10","author":"Joung","year":"2015","journal-title":"PLoS One"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"e2018040","DOI":"10.4178\/epih.e2018040","article-title":"Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer.","volume":"40","author":"Jung","year":"2018","journal-title":"Epidemiol Health"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"489.e1","DOI":"10.1016\/j.urolonc.2022.07.016","article-title":"Multiple primary cancers in men with sporadic or familial prostate cancer: its clinical implications.","volume":"40","author":"Kim","year":"2022","journal-title":"Urol Oncol"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5534\/wjmh.230237","article-title":"Secondary cancer after androgen deprivation therapy in prostate cancer: a nationwide study.","volume":"43","author":"Kim","year":"2025","journal-title":"World J Mens Health"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","article-title":"Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study.","volume":"25","author":"Kjaer","year":"2024","journal-title":"Lancet Oncol"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3390\/cancers16132346","article-title":"Incidence and characteristics of multiple primary cancers: a 20-year retrospective study of a single cancer center in Korea.","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41598-020-80534-4","article-title":"Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"R19-20260327","first-page":"598","article-title":"Multiple primary cancer: an increasing health problem. Strategies for prevention in cancer survivors.","volume":"18","author":"L\u00f3pez","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"e6799","DOI":"10.1097\/MD.0000000000006799","article-title":"Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors.","volume":"96","author":"Lv","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R21-20260327","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1038\/s41598-024-55859-z","article-title":"Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.","volume":"14","author":"McLaughlin","year":"2024","journal-title":"Sci Rep"},{"key":"R22-20260327","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique.","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother Oncol"},{"key":"R23-20260327","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","article-title":"Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019.","volume":"397","author":"Reitsma","year":"2021","journal-title":"Lancet"},{"key":"R26-20260327","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R27-20260327","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jech.2007.063560","article-title":"New malignancies among cancer survivors: SEER cancer registries, 1973-2000.","volume":"62","author":"Supramaniam","year":"2008","journal-title":"J Epidemiol Commun Health"},{"key":"R28-20260327","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12885-021-08766-9","article-title":"Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study.","volume":"21","author":"Tanjak","year":"2021","journal-title":"BMC Cancer"},{"key":"R29-20260327","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2024.4397","article-title":"Long-term adverse effects and complications after prostate cancer treatment.","volume":"10","author":"Unger","year":"2024","journal-title":"JAMA Oncol"},{"key":"R30-20260327","doi-asserted-by":"crossref","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review.","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"R31-20260327","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"R32-20260327","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clon.2009.05.008","article-title":"Estimated dose to the rectum and colon in prostate cancer patients treated with exclusive radiation therapy presenting a secondary colorectal malignancy.","volume":"21","author":"Weber","year":"2009","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R33-20260327","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00008469-200508000-00002","article-title":"International rules for multiple primary cancers (ICD-0 third edition).","volume":"14","year":"2005","journal-title":"Eur J Cancer Prev"},{"key":"R35-20260327","doi-asserted-by":"crossref","first-page":"638","DOI":"10.21037\/atm-20-2059","article-title":"Second primary malignancies among cancer patients.","volume":"8","author":"Zheng","year":"2020","journal-title":"Ann Transl Med"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:00:57Z","timestamp":1774591257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000977","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}